Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy

Blood

Volumn 90, Issue 8, 1997, Pages 2969-2977

  Estey, Elihu ^a,b   Thall, Peter ^a   Beran, Miloslav ^a   Kantarjian, Hagop ^a   Pierce, Sherry ^a   Keating, Michael ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CHROMOSOME 5; CHROMOSOME 7; CYTOGENETICS; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; TREATMENT OUTCOME;

EID: 0030765385     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.8.2969     Document Type: Article

References (44)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C, The French-American-British (FAB) Co-Operative Group: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189, 1982
2. Hirst WJR, Mufti GJ: Management of myelodysplastic syndromes. Br J Haematol 84:191, 1993
3. Estey E: Treatment of acute myelogenous leukemia and myelodysplastic syndromes. Semin Hematol 32:132, 1995
4. Hast R, Hellstrom E: Therapeutic aspects of myelodysplastic syndromes in chronic phase. Leuk Res 16:95, 1992
5. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. Blood 88:2841, 1996
6. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams W, Hewlett J, Willman C, Appelbaum FR: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717, 1995
7. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E III, for the Cancer and Leukemia Group B: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896, 1994
8. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924, 1992
9. Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato MK, Tsubaki K, Ohmoto E, Oh O, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Saito H, Ueda R, Ohno R, for the Japan Adult Leukemia Study Group: Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J Clin Oncol 14:204, 1996
10. Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S, for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto (GIMEMA) Leukemia Cooperative Groups: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217, 1995
11. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin JH: Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 13:560, 1995
12. Berman E, Heller G, Santorsa JA, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwar S, Young C, Clarkson B: Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666, 1991
13. Freireich EJ, Gehan EA, Sulman D, Boggs DR, Frei E III: The effect of chemotherapy on acute leukemia in the human. J Chron Dis 14:593, 1961
14. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7:1315, 1993
15. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 74:395, 1989
16. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W: Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52, 1992
17. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D: Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 59:425, 1985
18. Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079, 1996
19. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M: Treatment of newly-diagnosed acute promyelocytic leukemia without cytosine arabinoside. J Clin Oncol 15:483, 1997
20. Cason J, Trujillo J, Estey E, Huh Y, Freireich E, Stass S: Peripheral acute leukemia: High peripheral but low-marrow blast count. Blood 74:1758, 1989
21. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813, 1990
22. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierce S, Frireich EJ, Deisseroth A, Keating M: Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671, 1994
23. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley and Sons, 1980, p 120
24. Estey E: Treatment of refractory AML. Leukemia 10:932, 1996
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
26. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
27. Harrington D, Fleming TR: A class of rank test procedures for censored survival data. Biometrika 69:133, 1982
28. Harrington D, Fleming TR: Counting Processes and Survival Analysis. New York, NY, John Wiley and Sons, 1991
29. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187, 1972
30. Therneau TM: A Package for Survival Analysis in S. Rochester, MN, Mayo Clinic Foundation, 1994
31. Therneau TM, Grambsch PM, Fleming TR: Martingale-based residuals for survival models. Biometrika 77:147, 1990
32. Grambsch PM, Therneau TM: Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 51:1469, 1995
33. Cleveland WS: Robust locally-weighted regression and smoothing scatterplots. J Am Stat Assoc 74:829, 1979
34. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515, 1994
35. Becker RA, Chambers JM, Wilks ARA: The New S Language. Wadsworth, CA, Pacific Grove, 1988
36. Neder J, Kutner MH, Nachtsheim CJ, Wasserman W: Applied Linear Statistical Models (ed 4). Boston, MA, Irwin, 1996
37. Mertelsmann R, Thaler HT, To L, Gee TS, McKenzie S, Schauer P, Friedman A, Arlin Z, Cirrincione C, Clarkson B: Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56:773, 1980
38. Armitage JO, Dick FR, Needleman SW, Burns CP: Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 65:601, 1981
39. Tricot G, Boogaerts MA: The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 63:477, 1986
40. De Witte T, Muus P, De Pauw B, Haanen C: Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66:831, 1990
41. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F: Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497, 1991
42. Economopoulos T, Papageorgiou E, Stathakis N, Constantinidou M, Parharidou A, Kostourou A, Dervenoulas J, Raptis S: Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Leuk Res 20:385, 1996
43. Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S: AML-associated cytogenetic abnormalities (inv(16), del(16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol 6:43, 1992
44. Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD: Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British Criteria: A Cancer and Leukemia Group B study. J Clin Oncol 14:2486, 1996